FTH net incomeQ3 2026-$20.40M
FTH net income was -$20.40M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$4.57M a year earlier. For the full fiscal 2025 it was -$21.09M, compared with -$30.16M in fiscal 2024.
Faeth Therapeutics Inc. (FTH) financials
For the twelve months ended Sep 30, 2026, Faeth Therapeutics Inc. reported -$211.36M of net income.
- Net income, TTM
- -$211.36M
- Free cash flow, TTM
- -$43.28M
- EPS, diluted, TTM
- -$138.82
- Cash
- $14.18M
- Market cap
- $569.9M
FY2020FY2025
FY2020FY2025
FTH revenue and earnings growth
FTH EPSQ3 2026-$0.79
FTH diluted EPS was -$0.79 in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2025 it was -$16.72, compared with -$24.01 in fiscal 2024.
FTH free cash flowQ3 2026-$13.01M
FTH free cash flow was -$13.01M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$3.59M a year earlier. For the full fiscal 2025 it was -$20.47M, compared with -$24.82M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Selling, general and admin | $11.33M | $13.04M | $18.77M | $19.80M | $15.82M | $7.53M |
| Operating income | -$22.29M | -$32.61M | -$37.06M | -$50.19M | -$37.48M | -$19.45M |
| Interest expense | $32.0K | $90.0K | $144.0K | $219.0K | $670.0K | $1.69M |
| Pre-tax income | -$21.09M | -$30.16M | - | - | - | - |
| Income tax | $0 | $0 | - | - | - | - |
| Net income | -$21.09M | -$30.16M | -$34.10M | -$48.59M | -$36.79M | -$20.10M |
| EPS, basic | -$16.72 | -$24.01 | -$24.40 | -$31.60 | -$26.60 | -$250.60 |
| EPS, diluted | -$16.72 | -$24.01 | -$24.40 | -$31.60 | -$26.60 | -$250.60 |
| Diluted shares | 1.3M | 1.3M | 1.4M | 1.5M | 1.4M | 80,607 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $8.67M | $9.99M | $13.01M | $17.80M | $7.16M | $16.60M |
| Short-term investments | - | - | - | - | $140.46M | - |
| Current assets | $21.51M | $41.93M | $67.25M | $108.59M | $148.54M | $20.08M |
| Total assets | $22.90M | $45.36M | $74.37M | $118.38M | $153.22M | $21.43M |
| Current liabilities | $4.25M | $5.45M | $5.64M | $9.07M | $4.89M | $4.83M |
| Long-term debt | - | - | - | - | - | $567.0K |
| Total debt | - | - | - | - | - | $567.0K |
| Total liabilities | $4.31M | $6.97M | $9.48M | $14.97M | $6.71M | $5.54M |
| Shareholders' equity | $18.59M | $38.39M | $64.89M | $103.41M | $146.51M | -$56.44M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$20.45M | -$24.67M | -$32.02M | -$39.03M | -$30.26M | -$17.70M |
| Capital expenditures | $16.0K | $146.0K | $180.0K | $321.0K | $2.03M | $1.21M |
| Free cash flow | -$20.47M | -$24.82M | -$32.20M | -$39.35M | -$32.28M | -$18.91M |
| Investing cash flow | $19.77M | $22.44M | $38.41M | $49.95M | -$143.12M | -$1.40M |
| Financing cash flow | -$645.0K | -$787.0K | -$11.17M | -$287.0K | $163.94M | $35.45M |
| Share repurchases | - | - | $10.38M | - | - | - |
| Stock-based compensation | $1.27M | $3.13M | $4.45M | $5.81M | $5.66M | $1.49M |
| Depreciation and amortization | $122.0K | $551.0K | $571.0K | $614.0K | $685.0K | $209.0K |
Key ratios
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, general and admin | $10.35M | $9.21M | $19.71M | $2.79M | $2.31M | $2.67M | $3.55M | $2.83M | $3.19M | $3.20M | $3.81M | $3.65M |
| Operating income | -$22.09M | -$18.39M | -$170.63M | -$4.96M | -$4.85M | -$5.21M | -$7.27M | -$8.27M | -$7.82M | -$7.79M | -$8.73M | -$8.14M |
| Interest expense | - | - | - | $3.0K | $6.0K | $10.0K | $13.0K | $17.0K | $21.0K | $24.0K | $28.0K | $31.0K |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | - |
| Net income | -$20.40M | -$16.01M | -$170.24M | -$4.72M | -$4.57M | -$4.94M | -$6.86M | -$7.77M | -$7.25M | -$7.14M | -$7.99M | -$7.41M |
| EPS, basic | -$0.79 | -$2.84 | -$131.45 | -$3.74 | -$3.62 | -$3.91 | -$5.45 | -$6.15 | -$5.77 | -$5.69 | -$6.40 | -$6.00 |
| EPS, diluted | -$0.79 | -$2.84 | -$131.45 | -$3.74 | -$3.62 | -$3.91 | -$5.45 | -$6.15 | -$5.77 | -$5.69 | -$6.40 | -$6.00 |
| Diluted shares | 25.8M | 5.6M | 1.3M | - | 1.3M | 1.3M | 1.3M | - | 1.3M | 1.3M | 1.3M | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $14.18M | $26.90M | $152.32M | $8.67M | $10.56M | $12.56M | $9.88M | $9.99M | $19.13M | $11.89M | $10.96M | $13.01M |
| Current assets | $177.84M | $188.66M | $204.23M | $21.51M | $25.79M | $29.57M | $35.68M | $41.93M | $48.10M | $53.94M | $60.23M | $67.25M |
| Goodwill | $0 | $0 | $0 | - | - | - | - | - | - | - | - | - |
| Total assets | $178.95M | $189.31M | $205.38M | $22.90M | $27.59M | $31.78M | $38.27M | $45.36M | $53.25M | $59.80M | $66.69M | $74.37M |
| Current liabilities | $11.03M | $9.58M | $14.19M | $4.25M | $4.44M | $3.87M | $5.23M | $5.45M | $5.44M | $4.95M | $4.99M | $5.64M |
| Total liabilities | $11.09M | $9.58M | $14.19M | $4.31M | $4.58M | $4.47M | $6.29M | $6.97M | $7.47M | $7.61M | $8.22M | $9.48M |
| Shareholders' equity | $161.10M | $172.96M | -$137.29M | $18.59M | $23.01M | $27.31M | $31.99M | $38.39M | $45.78M | $52.19M | $58.47M | $64.89M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$13.00M | -$15.67M | -$10.73M | -$3.86M | -$3.59M | -$5.91M | -$7.09M | -$5.79M | -$5.47M | -$5.79M | -$7.62M | -$6.16M |
| Capital expenditures | $3.0K | $0 | $6.0K | $0 | $0 | $16.0K | $0 | $0 | $0 | $109.0K | $37.0K | $0 |
| Free cash flow | -$13.01M | -$15.67M | -$10.74M | -$3.86M | -$3.59M | -$5.92M | -$7.09M | -$5.79M | -$5.47M | -$5.90M | -$7.65M | -$6.16M |
| Investing cash flow | $175.0K | -$108.07M | -$31.44M | $2.08M | $1.74M | $8.76M | $7.19M | -$3.15M | $12.91M | $6.91M | $5.77M | $8.26M |
| Financing cash flow | $104.0K | -$1.68M | $185.83M | -$111.0K | -$152.0K | -$168.0K | -$214.0K | -$194.0K | -$204.0K | -$180.0K | -$209.0K | -$431.0K |
| Share repurchases | - | - | - | - | - | - | - | - | - | - | - | $252.0K |
| Stock-based compensation | $8.52M | $4.48M | $12.90M | $295.0K | $254.0K | $264.0K | $461.0K | $391.0K | $733.0K | $795.0K | $1.22M | $1.10M |
| Depreciation and amortization | $17.0K | $25.0K | $29.0K | $30.0K | $30.0K | $32.0K | $30.0K | $139.0K | $140.0K | $135.0K | $137.0K | $135.0K |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 16.12 | 19.69 | 14.39 | 5.06 | 5.81 | 7.64 | 6.82 | 7.70 | 8.84 | 10.90 | 12.07 | 11.92 |
Source: XBRL data Faeth Therapeutics Inc. files with the SEC, latest filing dated Nov 3, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-20, first reported Aug 5, 2025.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
FTH peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| FTH | - | - | -$211.36M | - | $569.9M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.27T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $664.95B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $514.92B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $361.71B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $310.17B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.10B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $190.39B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.51B |
FTH FAQ
6 questionsIs FTH profitable?
No. Faeth Therapeutics Inc. reported a net loss of $211.36M for the twelve months ended Sep 30, 2026.How much cash and debt does FTH have?
Faeth Therapeutics Inc. reported $14.18M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is FTH free cash flow?
Faeth Therapeutics Inc. generated -$43.28M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$43.27M less capital expenditures.What is FTH earnings per share?
Diluted earnings per share were -$138.82 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.When did FTH last report financial results?
The latest statements here come from Faeth Therapeutics Inc.'s 10-Q filed on Nov 3, 2026, covering the period ended Sep 30, 2026.Where does this FTH financial data come from?
Quantisnow builds these statements from the structured XBRL data Faeth Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.